60 questions about SCLC with Dr. Greg Kalemkerian Part 2
Roquefort Therapeutics Acquires Global Rights to TACC3 Inhibitor AO-252 in £31.9M Deal, Pivoting to Clinical-Stage Oncology
15 Posts Not To Miss from ESGO 2026
Rezatapopt Shows Early Activity in TP53 Y220C–Mutated Solid Tumors
LITESPARK-022 Update: Adjuvant Belzutifan + Pembrolizumab in High-Risk Clear Cell Renal Cell Carcinoma
15 Posts Not To Miss From ASCO GU 2026
MSK Awards and Appointments January 2026
Guru Sonpavde: Early Success With EV and FGFR Inhibitor in Bladder Cancer Patients
